KR102301463B1 - 사이토메갈로바이러스의 치료를 위한 조성물 및 방법 - Google Patents

사이토메갈로바이러스의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102301463B1
KR102301463B1 KR1020147015909A KR20147015909A KR102301463B1 KR 102301463 B1 KR102301463 B1 KR 102301463B1 KR 1020147015909 A KR1020147015909 A KR 1020147015909A KR 20147015909 A KR20147015909 A KR 20147015909A KR 102301463 B1 KR102301463 B1 KR 102301463B1
Authority
KR
South Korea
Prior art keywords
delete delete
virus
polypeptide
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147015909A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095556A (ko
Inventor
데이비드 이. 앤더슨
안느-까뜨린느 플뤼키거
Original Assignee
배리에이션 바이오테크놀로지스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리에이션 바이오테크놀로지스 아이엔씨. filed Critical 배리에이션 바이오테크놀로지스 아이엔씨.
Priority to KR1020197025818A priority Critical patent/KR102340558B1/ko
Publication of KR20140095556A publication Critical patent/KR20140095556A/ko
Application granted granted Critical
Publication of KR102301463B1 publication Critical patent/KR102301463B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
KR1020147015909A 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법 Active KR102301463B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020197025818A KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025818A Division KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20140095556A KR20140095556A (ko) 2014-08-01
KR102301463B1 true KR102301463B1 (ko) 2021-09-14

Family

ID=48290708

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147015909A Active KR102301463B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법
KR1020197025818A Active KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197025818A Active KR102340558B1 (ko) 2011-11-11 2012-11-09 사이토메갈로바이러스의 치료를 위한 조성물 및 방법

Country Status (14)

Country Link
US (3) US9777043B2 (enExample)
EP (2) EP3854416A1 (enExample)
JP (2) JP6232544B2 (enExample)
KR (2) KR102301463B1 (enExample)
CN (3) CN111995664B (enExample)
AU (3) AU2012335277B2 (enExample)
BR (2) BR112014011229B1 (enExample)
CA (2) CA2889659C (enExample)
DK (1) DK2776567T3 (enExample)
ES (1) ES2874233T3 (enExample)
MX (2) MX353189B (enExample)
PT (1) PT2776567T (enExample)
RU (2) RU2019139064A (enExample)
WO (1) WO2013068847A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148275A2 (en) 2009-06-18 2010-12-23 Kiyatec, Llc Bioreactor system
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2889659C (en) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2831285B1 (en) * 2012-03-27 2019-10-30 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3158058B1 (en) 2014-06-18 2019-04-17 MorphoSys AG Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
JP7059179B2 (ja) 2015-10-20 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019209632A1 (en) * 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
CN112638411B (zh) 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3142110A1 (en) * 2019-05-31 2020-12-03 Variation Biotechnologies Inc. Immunotherapeutic compositions for treatment of glioblastoma multiforme
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
CN114466659A (zh) * 2019-09-09 2022-05-10 葛兰素史克生物有限公司 免疫治疗组合物
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The HBsAgの精製方法
EP0436537A4 (en) * 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
JP2003512305A (ja) * 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
DK2311848T3 (da) 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
EP1651666B1 (en) 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20090123494A1 (en) 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
US20110250675A1 (en) 2008-03-26 2011-10-13 Life Technologies Corporaiton Virus-Like Particle Mediated Cellular Delivery
CA2889659C (en) 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
CN106102769A (zh) * 2013-12-11 2016-11-09 促进军事医学的亨利·M·杰克逊基金会公司 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128338A2 (en) * 2009-05-08 2010-11-11 Henderson Morley Plc Vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Expert opinion on biological therapy 1.3: 401-412 (2001. 5.1.)*
Science translational medicine 3.94 94ra71-94ra71 (2011. 8. 3.)*
Science translational medicine,제3권,94호,94ra71,1-8면 (2011.08.) 1부.*

Also Published As

Publication number Publication date
CN107875382A (zh) 2018-04-06
BR112014011229B1 (pt) 2021-10-13
AU2020264275B2 (en) 2023-12-14
US20230272013A1 (en) 2023-08-31
AU2018203538A1 (en) 2018-06-07
CN107875382B (zh) 2024-03-08
CN104271745A (zh) 2015-01-07
JP2015505299A (ja) 2015-02-19
US11248026B2 (en) 2022-02-15
CN111995664B (zh) 2024-08-02
US20170349634A1 (en) 2017-12-07
BR112014011229A2 (pt) 2017-05-09
CN111995664A (zh) 2020-11-27
AU2020264275A1 (en) 2020-11-26
CA3166278A1 (en) 2013-05-16
RU2019139064A (ru) 2020-01-27
AU2012335277B2 (en) 2018-06-14
US20140308308A1 (en) 2014-10-16
RU2737530C1 (ru) 2020-12-03
KR20190104644A (ko) 2019-09-10
ES2874233T3 (es) 2021-11-04
JP6232544B2 (ja) 2017-11-22
DK2776567T3 (da) 2021-04-26
CA2889659C (en) 2023-03-14
EP3854416A1 (en) 2021-07-28
EP2776567A4 (en) 2015-12-30
KR20140095556A (ko) 2014-08-01
JP6657150B2 (ja) 2020-03-04
WO2013068847A2 (en) 2013-05-16
JP2018023374A (ja) 2018-02-15
WO2013068847A3 (en) 2014-10-30
BR122019027913B1 (pt) 2021-11-30
KR102340558B1 (ko) 2021-12-21
MX2014005653A (es) 2014-09-04
MX353189B (es) 2018-01-05
EP2776567B1 (en) 2021-01-20
MX387666B (es) 2025-03-18
EP2776567A2 (en) 2014-09-17
CA2889659A1 (en) 2013-05-16
PT2776567T (pt) 2021-05-25
US12421283B2 (en) 2025-09-23
AU2012335277A1 (en) 2014-06-12
US9777043B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
AU2020264275B2 (en) Compositions and methods for treatment of cytomegalovirus
JP2003529559A (ja) 新規用途
KR20160060659A (ko) Hiv 감염증의 rna-유도 치료를 위한 방법 및 조성물
JP2010187681A (ja) HIVに対する免疫のためのgp120と、Nef及び/又はTatを含むワクチン
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
CN110256539B (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
CN111729078B (zh) 鸡传染性贫血病毒基因工程疫苗
JP4411213B2 (ja) ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン
US11154611B2 (en) Vaccine against bovine leukemia virus
JP2005519959A (ja) Hivに対する強化された免疫応答を誘導する方法
CN114729375A (zh) 源自噬菌体t5的纳米颗粒的生产和功能化以及治疗用途
CA2528094A1 (en) Expression vectors for stimulating an immune response to cancer antigens
TWI633114B (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物
TWI659966B (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物
US20030118601A1 (en) FIV vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140611

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171025

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190228

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200218

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210218

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210907

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210907

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240910

Start annual number: 4

End annual number: 4